Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 6/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972548 | 0.93 | POLB (0.40) | POLBGAANPSR1TSHRPRKCA | |
| SCHEMBL12392875 | 0.93 | POLB (0.40) | POLBGAANPSR1TSHRPRKCA | |
| SCHEMBL4258156 | 0.89 | POLB (0.48) | POLBGAANPSR1TSHRPRKCA | |
| SCHEMBL13686742 | 0.86 | ALDH1A1 (0.45) | POLBGAANPSR1TSHRPRKCA | |
| SCHEMBL4156534 | 0.86 | POLB (0.41) | POLBGAANPSR1TSHRPRKCA | |
| SCHEMBL20286477 | 0.84 | ALDH1A1 (0.48) | POLBGAANPSR1TSHRPRKCA | |
| SCHEMBL12901631 | 0.83 | PRKCA (0.38) | POLBGAANPSR1TSHRPRKCA | |
| SCHEMBL31629763 | 0.83 | TSHR (0.41) | POLBGAANPSR1TSHRALDH1A1 | |
| SCHEMBL11340608 | 0.82 | POLB (0.39) | POLBGAANPSR1PRKCA | |
| SCHEMBL5021535 | 0.82 | POLB (0.44) | POLBGAANPSR1TSHRPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11639364-B2 | Potent sialyltransferase inhibitors | STICHTING RADBOUD UNIVERSITEIT (NL) | 2023-05-02 | — | — | US | disclosed |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| CN-111349185-B | Solid catalyst for propylene polymerization and method for producing block copolymer using the same | 韩华道达尔能源有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11427657-B2 | Solid catalyst for propylene polymerization and method of producing block copolymer using the same | HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) | 2022-08-30 | — | — | US | disclosed |
| EP-3596064-B1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-10730999-B2 | Dendrimer-drug conjugates | STARPHARMA PTY LTD (AU) | 2020-08-04 | — | — | US | disclosed |
| CN-111349185-A | Solid catalyst for propylene polymerization and method for producing block copolymer using the same | 韩华道达尔有限公司 | 2020-06-30 | — | — | CN | disclosed |
| US-20200199266-A1 | Solid Catalyst For Propylene Polymerization And Method Of Producing Block Copolymer Using The Same | HANWHA TOTALENERGIES PETROCHEMICAL CO., LTD. (KR) | 2020-06-25 | — | — | US | disclosed |
| EP-1092720-A2 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-5886179-A | NUCLEOTIDE PHOSPHONATE ESTERS HYDROLYZABLE IN VIVO TO THE CORRESPONDING NUCLEOTIDE PHOSPHONATE AS VIRICIDES | GILEAD SCIENCES, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0874858-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5717095-A | PHOSPHONATES CYTOSINE COMPOUND | GILEAD SCIENCES, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5656745-A | AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997024361-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730999-B2 | Dendrimer-drug conjugates | DNPEP, CLTA, ADM2 | POLB 2504/4885GAA 505/4885NPSR1 2497/4885 |
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | POLB 758/4885GAA 1269/4885NPSR1 1252/4885 |
| US-11639347-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | POLB 2183/4885GAA 328/4885NPSR1 3547/4885 |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | POLB 2183/4885GAA 328/4885NPSR1 3547/4885 |
| US-11639364-B2 | Potent sialyltransferase inhibitors | NEU1, NMT1, NEU2 | POLB 4243/4885GAA 412/4885NPSR1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.